UNCLAIMED
RapidAI
Overview
RapidAI is a software company based in the United States, specializing in healthcare software solutions that leverage artificial intelligence (AI) to enhance clinical decision-making in vascular medicine. Founded in 2012, the company employs between 201 and 500 individuals and reported revenue of approximately $47.26 million. RapidAI's primary focus is on developing AI-powered clinical decision support (CDS) systems that streamline clinical and administrative workflows, ultimately improving patient care. Their technology processes large volumes of medical imaging data and converts unstructured clinical notes into actionable insights. The company has contributed to significant advancements in stroke treatment protocols, as evidenced by its involvement in landmark clinical trials that influenced guidelines from the American Heart Association and the American Stroke Association. RapidAI's products, such as Rapid Aneurysm, are designed to accurately identify and measure cerebral aneurysms, providing critical data that assists healthcare professionals in assessing rupture risks and determining appropriate treatment options. The company's commitment to integrating sophisticated AI techniques into healthcare aims to enhance the precision and efficiency of medical decision-making.